Galaxy Therapeutics

🌍 SEAL IT IDE Trial Update 🌍 We’re thrilled to share the 4th case of 2025 in the SEAL IT study! This milestone was achieved today at Texas Stroke Institute by Dr. Bhuva and her team. A big thank you to everyone involved in driving innovation forward. Together, we continue to advance the field of neurointervention. #Neurointervention #MedicalInnovation #ClinicalResearch #BrainHealth #GalaxyTherapeutics 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

🌍 SEAL IT IDE Trial Update 🌍 Kicking off 2025 with an incredible milestone! We’re thrilled to announce the first SEAL IT case of the year, successfully performed by Dr. Brian Jankowitz and his team at JFK Hospital, NJ. As we start the year strong with 4 cases scheduled today, we’re grateful for the dedication of healthcare professionals driving innovation in neurointervention. Thank you, Dr. Jankowitz, for your commitment to advancing care for brain aneurysm patients. Stay tuned for more updates as SEAL IT progresses! #SEALIT #GalaxyTherapeutics #Neurointervention #InnovationInCare #ClinicalTrials 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

✨ Happy New Year 2025! ✨ As we step into a new year, we extend our warmest wishes to all our followers, partners, and collaborators. May 2025 bring innovation, success, and progress in all your endeavors. Stay tuned for what’s coming next from Galaxy Therapeutics—together, let’s continue shaping the future. #HappyNewYear #GalaxyTherapeutics #SEAL #SEALIT #SEALME

🌟 Ending the Year on a High Note! 🌟 As the year comes to a close, we are thrilled to share some incredible news: 5 patients enrolled yesterday across our SEAL IT IDE Trial (4 cases) and 1 Compassionate Use case! ✅ 1 at JFK, New Jersey by Dr. Brian Jankowitz ✅ 3 at Cleveland Clinic, Ohio by Dr. Mark Bain ✅ 1 at Montefiore, New York by Dr. David Altschul This progress brings us to an incredible 62 patients enrolled to date! We extend our heartfelt gratitude to the participating physicians and their teams for their dedication and expertise. As we close 2024, we’re energized to continue advancing neurointervention into 2025. Stay tuned for what’s ahead! 🚀 #Neurointervention #Innovation #ClinicalResearch #GalaxyTherapeutics #SEALIT #SEAL 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

❄️ As the year comes to a close, we at Galaxy Therapeutics reflect on a journey defined by innovation, collaboration, and gratitude. ❄️ This winter season, we want to thank all the healthcare professionals, research partners, and supporters who have joined us in advancing neurointervention. Together, we are shaping a future of better care and meaningful progress. May this time of year bring warmth, connection, and inspiration to all. Here’s to unity and innovation as we look forward to the opportunities ahead in 2025! #GalaxyTherapeutics #Innovation #Gratitude #Unity #WinterSeason

🌍 SEAL Me Registry Update 🌍 Exciting news from New Zealand! 🇳🇿 Another case has been successfully completed as part of the SEAL Me pre-clinical registry. Each case brings us closer to understanding and shaping the future of aneurysm treatment. We’re grateful to our international collaborators for their vital contributions to this journey. Together, we’re advancing the frontier of neuroinnovation. 🌏💡 #SEALMe #Neuroinnovation #BrainAneurysm #CollaborativeResearch #GalaxyTherapeutics 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺.   𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

🌍 SEAL IT IDE Trial Update 🌍 We’re thrilled to share another milestone for the SEAL IT IDE trial! 🧠 Dr. Dandapat successfully completed his first case at Aurora St. Luke’s Medical Center in Wisconsin. 🔹 Case Details: • Treated an MCA aneurysm using a 9×3 SEAL device. Congratulations to Dr. Dandapat and the team for advancing innovation in neurointervention! 🚀 #Neurointervention #BrainAneurysm #SEALIT #InnovationInMedicine #GalaxyTherapeutics 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺.   𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

🌟 SEAL IT IDE Case Highlight 🌟 Dr. Tonetti at Cooper University Hospital, NJ, successfully managed a basilar tip aneurysm with significant vertebral stenosis in the SEAL IT IDE trial. This remarkable case showcases the expertise driving innovation in neurointervention. Grateful to Dr. Tonetti and the Cooper team for their contribution! #GalaxyTherapeutics #SEALITTrial #NeuroIntervention #ClinicalEvidence 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺.   𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.

51 year old with complex shaped Acomm aneurysm ( 4mm) treated with Seal device. Easy to deploy , detach and conforms really well. #Galaxytherapeutics #Sealit!

🌟 SEAL IT IDE Case Highlight 🌟 A tough left ACOM aneurysm case with a 90-degree turn to access, treated by Dr. Jankowitz at JFK Hospital, NJ. This highlights the precision and innovation required to advance neurointervention. Thank you, Dr. Jankowitz and team, for this outstanding contribution to the SEAL IT trial. #GalaxyTherapeutics #SEALITTrial #NeuroIntervention #ClinicalEvidence 𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘥𝘦𝘷𝘪𝘤𝘦. 𝘓𝘪𝘮𝘪𝘵𝘦𝘥 𝘣𝘺 𝘍𝘦𝘥𝘦𝘳𝘢𝘭 (𝘜.𝘚.) 𝘭𝘢𝘸 𝘵𝘰 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺.   𝘊𝘈𝘜𝘛𝘐𝘖𝘕: 𝘐𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘢𝘷𝘢𝘪𝘭𝘢𝘣𝘭𝘦 𝘧𝘰𝘳 𝘴𝘢𝘭𝘦 𝘶𝘯𝘵𝘪𝘭 𝘊𝘌 𝘮𝘢𝘳𝘬𝘦𝘥.